MYNZMainz Biomed BV
About Mainz Biomed BV
Mainz Biomed (NASDAQ:MYNZ) is a dynamic company engaged in developing cutting-edge molecular genetics diagnostic solutions for early disease detection and prevention. Mainz Biomed focuses on empowering healthcare professionals and enhancing patient care through innovative diagnostics. Their projects include the development of ColoAlert, a convenient and highly effective early detection test for colorectal cancer, alongside other pipeline products that target various gastrointestinal diseases. The company aims to transform diagnostic processes, making them more accessible and efficient for people worldwide, ultimately improving outcomes and saving lives.
What is MYNZ known for?
Snapshot
Public US
Ownership
2008
Year founded
65
Employees
Mainz, Germany
Head office
1 of 3
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
Federal Republic of Germany
Products and/or services of Mainz Biomed BV
- ColoAlert offers highly accurate, non-invasive, and easy-to-use colon cancer detection through advanced DNA technology.
- GenoStrip: This is a platform technology for the detection of pathogens in environments on a molecular genetic basis. It's still in the early stages of development, but has potential applications in various fields including healthcare, food safety, and environmental monitoring.
- PancAlert aims at early detection of pancreatic cancer, utilizing biomarker technology for non-invasive testing.
- Research & Development: Mainz Biomed also conducts research and development for other potential diagnostic solutions, focusing on utilizing known and existing biomarkers for reliable and accessible tests.
Mainz Biomed BV executive team
- Mr. Guido BaechlerCEO & Executive Director
- Mr. William J. Caragol CPACFO & Senior VP
- Dr. Christopher Von Toerne P.M.P., Ph.D.Chief Operating Officer
- Mr. Stefan ErlachHead of Human Resources